MediGene company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

medigene.com

Founded Year

1994

Stage

IPO | IPO

Date of IPO

6/2/2000

About MediGene

Medigene is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from a marketed product, Veregen, which is distributed by commercial partners companies. Medigene has two drug candidates in clinical trials, EndoTAG-1 and RhuDex, and is developing a vaccine technology.

MediGene Headquarter Location

Lochhamer Str. 11

Planegg-Martinsried, D-82152,

Germany

+49 89 20 00 33 29 20

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MediGene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MediGene is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

MediGene Patents

MediGene has filed 42 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/1/2016

4/5/2022

Immunology, Human cell lines, Immune system, Clusters of differentiation, Molecular biology

Grant

Application Date

6/1/2016

Grant Date

4/5/2022

Title

Related Topics

Immunology, Human cell lines, Immune system, Clusters of differentiation, Molecular biology

Status

Grant

Latest MediGene News

New CEOs at CorMedix, Medigene

May 13, 2022

MAY 12, 2022 | 5:24 PM PDT | BIOCENTURY | MANAGEMENT TRACKSNEW CEOS AT CORMEDIX, MEDIGENEBY Plus updates from Elicio, Rejuvenate, Canbridge and morehttps://www.biocentury.com/article/643594/new-ceos-at-cormedix-medigene© 2022 BioCentury Inc. All Rights Reserved

MediGene Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MediGene Rank

  • When was MediGene founded?

    MediGene was founded in 1994.

  • Where is MediGene's headquarters?

    MediGene's headquarters is located at Lochhamer Str. 11, Planegg-Martinsried.

  • What is MediGene's latest funding round?

    MediGene's latest funding round is IPO.

  • Who are the investors of MediGene?

    Investors of MediGene include Star Ventures and Advent Life Sciences.

  • Who are MediGene's competitors?

    Competitors of MediGene include Promedtek, Mercator MedSystems, Synapse Biomedical, eNeura Therapeutics, Vapotherm and 12 more.

You May Also Like

A
Aspire Medical

Aspire Medical is developing a new therapy for treating obstructive sleep apnea.

H
Health Care Solutions

Respiratory and infusion therapy for patients at home. Acquired by Lincare Holdings, Inc.

Synapse Biomedical Logo
Synapse Biomedical

Synapse Biomedical (SBI) was founded to commercialize the NeuRx Diaphragm Pacing System (DPS) that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency.

N
Nuhalaboratorio-Nosemedical

Nuhalaboratorio-nosemedical Is A Diagnostic company That Develops And Manufactures Equipment For The Analysing Of Nasal Function.

P
Pathfinder Therapeutics

Pathfinder Therapeutics (PTI) is the developer of Explorer, an image-guided "GPS" device that enables physicians to accurately and efficiently guide the delivery of cancer therapeutics (usually resection and/or ablation) in soft-tissue organs. Explorer is cleared by the FDA in the category of Intraoperative Soft Tissue Tracking. Scout, the company's advanced 3D planning software, provides highly detailed visual and volumetric information for preoperative assessment, thus enabling clinicians to visualize the site of disease, plan the resection and/or ablation and monitor the resultant effects.

Promedtek Logo
Promedtek

ProMedTek is developing Composite Therapy for problem wounds in the medical device technology market.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.